EUCTR2006-004172-12-IT进行中（未招募）不适用
A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis versus Lucentis monotherapy in patients with subfoveal choroidal neovascularization secondary to age related macular degeneration - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients of any race 50 years or older Primary or recurrent active subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component The total area of CNV including both classic and occult components encompassed within the lesion must be 50 of the total lesion area as defined by fluorescein angiography FA The total lesion are must have the Greatest Linear Dimension GLD 8804; 5400 microns 9 MPS Disc Areas DA If the lesion is classified as occult with no classic CNV component, the lesion must have evidence of recent disease progression as defined in the study glossary under active lesion BCVA letter score in the study eye between 73-24 approximately 20/40 to 20/320 Snellen equivalent using an ETDRS chart measured at 4 meters distance Patients who provide written and informed consent according to legal requirements, and who have signed the consent form prior to initiation of any study procedure Patients willing and able to comply with all study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Ocular concomitant conditions/ diseases Presence of angioid streaks, presumed ocular histoplasmosis syndrome, pathologic myopia -8 or more with evidence of posterior segment abnormalities consistent with pathologic myopia , or CNV secondary to causes other than AMD Presence of fibrosis, hemorrhage, pigment epithelial detachments, or other hypofluorescent lesions obscuring greater than 50 of the CNV lesion Tear rip of the retinal pigment epithelium Active, or history of, ocular inflammation or infection in the study eye within 30 days prior to Screening Uncontrolled glaucoma in the study eye defined as intraocular pressure, IOP 8805; 25 mmHg despite treatment with two or more topical pharmacological anti-glaucomatous medication Any concurrent ocular condition in the study eye that may result in visual loss during the study Ocular treatments Prior Visudyne , external-beam radiation, subfoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy in the study eye Prior treatment with Macugen , Lucentis , Avastin bevacizumab or other anti-angiogenic compound or any investigational treatment e.g. Ruboxistaurin, Retaane anecortave acetate , squalamine, siRNA, VEGF-Trap etc. for neovascular AMD in the study eye treatment of the fellow eye is permitted if administered 30 days before Screening History of intraocular surgery in the study eye including pars plana vitrectomy, except for uncomplicated cataract surgery more than 60 days prior to screening History of YAG laser posterior capsulotomy in the study eye within 30 days prior to screening
研究者
相似试验
进行中（未招募）
不适用
A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - MONT BLANCEUCTR2006-004172-12-FRovartis Pharma Services AG250
进行中（未招募）
不适用
A 24-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - MONT BLANCSubfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)MedDRA version: 8.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationEUCTR2006-004172-12-DEovartis Pharma Services AG250
进行中（未招募）
1 期
Study assessing the efficacy and safety of Brolucizumab versus Aflibercept in patients with impaired vision due to diabetic macular oedemaDiabetic Macular EdemaMedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2019-001004-37-HUovartis Pharma AG495
进行中（未招募）
1 期
A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with impaired vision which is caused by new vessels (neovascularization) in the choroid and for which ranibizumab may have a positive impactVisual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)MedDRA version: 17.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10047571Term: Visual impairmentSystem Organ Class: 10015919 - Eye disordersEUCTR2012-005417-38-BEovartis Pharma Services AG187
进行中（未招募）
1 期
A 12-month study to evaluate the efficacy and safety of injections of 0.5mg ranibizumab into the eye of patients with vision loss caused byincreased accumulation of fluid within the intraretinal layers of the macula(macular edema) and for which ranibizumab may have a positive impactVisual impairment due to vascular endothelial growth factor (VEGF)driven macular edema (ME)MedDRA version: 17.0Level: PTClassification code 10025415Term: Macular oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10047571Term: Visual impairmentSystem Organ Class: 10015919 - Eye disordersEUCTR2012-005418-20-BEovartis Pharma Services AG187